Usage Examples
- The pre-approval inspection closed with three Form 483 observations, two of them on data integrity.
- We have eleven business days left on the Form 483 response and the root-cause analysis is not finished.
- Due diligence on the CDMO included pulling its Form 483 history across the last three inspections.
What is FDA Form 483?
FDA Form 483 is the written list of inspectional observations an FDA investigator hands to facility management at the close of an inspection, recording conditions that may violate the FD&C Act without constituting a final agency determination.
FDA Form 483 exists because Congress required the finding to reach the firm on site, not months later. Section 704(b) of the FD&C Act directs the investigator, before leaving the premises, to give the owner or agent in charge a written report of conditions or practices observed that in the investigator's judgment indicate a product is adulterated or held under insanitary conditions. Form 483 is that report.
FDA Form 483 covers what an investigator directly observed at one establishment during one inspection, written as numbered observations tied to specific conditions or practices. FDA Form 483 does not carry FDA's legal conclusion: the agency states the form does not constitute a final Agency determination of whether any condition violates the FD&C Act. Inspection classification and any advisory action are decided later, on the full inspection record.
FDA Form 483 is worked in practice as a 15-business-day sprint. FDA encourages firms to respond in writing with a corrective action plan and supporting documentation within 15 business days of issuance, and to implement it expeditiously. Quality and regulatory teams triage each observation, establish root cause, commit to corrections and systemic CAPA with dates, and attach evidence. Form 483 history later resurfaces in supplier due diligence.
Not to be confused with
- Warning Letter
- a Form 483 comes from the investigator at the site and records observed conditions; a Warning Letter comes from FDA afterwards and states the agency's position that significant violations exist. The 483 is inspectional; the Warning Letter is advisory action.
- CAPA
- CAPA is the quality-system process a firm runs to correct a problem and prevent recurrence; a Form 483 is the FDA document that frequently triggers one. Closing your CAPA does not close the Form 483, because the firm does not own that assessment.
- GMP
- GMP is the body of manufacturing requirements a facility must meet; a Form 483 is the record of where an investigator saw it fall short. A Form 483 can also capture clinical or laboratory conditions, so it is not a GMP-only artifact.
- Data integrity
- data integrity is an attribute the underlying records must have, and a frequent subject of Form 483 observations. It is a property of the evidence, not an FDA document or an enforcement step.
Form 483 obligations split between what the investigator must do at the close of inspection and what the firm should do after.
What you must do
- 1Take receipt of the written report of observed conditions from the investigator before he or she leaves the premises, and expect a copy to go to the SecretaryFD&C Act 704(b)(1)
- 2Expect the Form 483 to be issued to firm management at the conclusion of the inspection, and put the people who can commit to corrections in that close-out meetingFDA Form 483 FAQ - issuance
- 3Read each observation against the criterion FDA applied: whether the conditions or practices observed indicate a product has been adulterated, or is being prepared, packed, or held under conditions whereby it may become adulterated or rendered injurious to healthFDA Form 483 FAQ - observation criteria
- 4Respond in writing within 15 business days of issuance with a corrective action plan and supporting documentation, and implement that plan expeditiouslyFDA Form 483 FAQ - 15 business days
- 5Treat the observations as inspectional findings rather than adjudicated violations, because the Form 483 does not constitute a final Agency determination of whether any condition is in violationFDA Form 483 FAQ - not a final Agency determination
Common mistakes
Treating the 15 business days as optional
FDA encourages a corrective action plan with supporting documentation within 15 business days of issuance. A firm that sends a two-line acknowledgement and follows up six weeks later has spent the one window in which its own account of the problem, and its evidence, reaches FDA before the agency decides what the inspection record warrants.
Answering the observation instead of the condition
Form 483 observations describe conditions and practices, not paperwork gaps. A response that argues regulatory interpretation, or that offers retraining plus a revised SOP for each numbered item without root cause and without checking whether the same failure exists on other lines, batches, or sites, leaves the condition in place. It reappears at the next inspection, and a repeat observation is far harder to explain than a first one.
Reading a Form 483 as a verdict
FDA states the Form 483 does not constitute a final Agency determination of whether any condition is in violation. Firms that read it as a ruling go one of two wrong ways: over-conceding in writing, creating admissions that follow the site into later inspections and partner audits, or freezing until "FDA's final decision" arrives, which is not how the process works.
When This Matters
- The pre-approval inspection closed with three Form 483 observations, two of them on data integrity.
- We have eleven business days left on the Form 483 response and the root-cause analysis is not finished.
- Due diligence on the CDMO included pulling its Form 483 history across the last three inspections.
Frequently Asked Questions
No. A Form 483 records what one FDA investigator observed at one inspection and, per FDA, does not constitute a final Agency determination that any condition violates the FD&C Act. A Warning Letter is FDA's later advisory action, issued after the agency reviews the inspection record and the firm's response.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
